Related references
Note: Only part of the references are listed.Bezafibrate for an Inborn Mitochondrial Beta-Oxidation Defect
Jean-Paul Bonnefont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components
Jean Bastin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mitochondrial fatty acid oxidation defects-remaining challenges
Niels Gregersen et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: Toward a genotype-based therapy
S. Gobin-Limballe et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
PPARα-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation
Naomi van Vlies et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2007)
Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders
C. Angelini et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
PPARδ:: a dagger in the heart of the metabolic syndrome
GD Barish et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders
F Djouadi et al.
HUMAN MOLECULAR GENETICS (2005)
A mitochondrial tRNA Aspartate mutation causing isolated mitochondrial myopathy
S Seneca et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2005)
Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells
F Djouadi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2005)
Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism.: A new target for the treatment of metabolic syndrome
S Luquet et al.
BIOCHIMIE (2004)
Regulation of muscle fiber type and running endurance by PPARδ
YX Wang et al.
PLOS BIOLOGY (2004)
Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate
F Djouadi et al.
PEDIATRIC RESEARCH (2003)
Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration
O Mayer et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle
AJ Gilde et al.
ACTA PHYSIOLOGICA SCANDINAVICA (2003)
Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors
CH Lee et al.
ENDOCRINOLOGY (2003)
Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency
L Thuillier et al.
HUMAN MUTATION (2003)
Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts
F Djouadi et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Carnitine palmitoyltransferase II deficiency: A clinical, biochemical, and molecular review
E Sigauke et al.
LABORATORY INVESTIGATION (2003)
Fenofibrate in the treatment of dyslipidemia: A review of the data as they relate to the new suprabioavailable tablet formulation
J Najib
CLINICAL THERAPEUTICS (2002)
Lipid-lowering drugs and risk of myopathy:: A population based follow-up study
D Gaist et al.
EPIDEMIOLOGY (2001)
Share Paper
